Your session is about to expire
← Back to Search
Cognitive Behavioral Therapy for Suicide Prevention in Psychosis
N/A
Recruiting
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Aged between 18 to 65 years
Suicide ideation and/or attempt within 3 months of screening
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-months after baseline
Awards & highlights
Study Summary
This trial will test a modified form of Cognitive Behavioral Therapy specifically for people with suicidal thoughts or behaviors due to a schizophrenia spectrum disorder, to see if it is more effective than usual care.
Who is the study for?
This trial is for English-speaking adults aged 18-65 with a schizophrenia spectrum disorder who have had suicidal thoughts or behaviors in the last 3 months. It's not suitable for those needing emergency care, with impaired cognitive capacity, or deemed inappropriate for behavioral treatment.Check my eligibility
What is being tested?
The study tests Cognitive Behavioral Suicide Prevention tailored for psychosis (CBSPp) against standard services (SAU). Participants will be randomly assigned to one of these two groups and evaluated over five months through interviews and assessments.See study design
What are the potential side effects?
Since this trial involves psychological therapy rather than medication, typical side effects associated with drugs are not expected. However, discussing sensitive topics like suicide may cause emotional discomfort.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 65 years old.
Select...
I have not had thoughts or attempts of suicide in the last 3 months.
Select...
I have been diagnosed with a schizophrenia spectrum disorder.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3-months after baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-months after baseline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Calgary Depression Rating Scale (CDRS) change from baseline
Columbia Suicide Severity Rating Scale (C-SSRS) change from baseline
Positive and Negative Syndrome Scale (PANSS) change from baseline
Secondary outcome measures
Beck Hopelessness Scale change from baseline
Defeat Scale (D Scale) change from baseline
Resilience Appraisals Scale (RAS) change from baseline
+3 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Cognitive Behavioral Suicide Prevention for psychosis (treatment group)Experimental Treatment1 Intervention
Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) is a behavioral treatment and will be delivered in 10 weekly individual therapy sessions in addition to standard/current services.
Group II: Services as Usual (SAU; comparison group)Active Control1 Intervention
Services as usual involve standard and current services that clients are eligible for receiving.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for psychosis include antipsychotic medications and cognitive-behavioral therapy (CBT). Antipsychotic medications work by altering the effects of neurotransmitters in the brain, particularly dopamine, to reduce symptoms like hallucinations and delusions.
Cognitive-behavioral therapy, including specialized forms like Cognitive Behavioral Suicide Prevention for psychosis (CBSPp), focuses on changing negative thought patterns and behaviors. This is crucial for psychosis patients as it helps them manage symptoms, reduce suicidal thoughts, and improve overall functioning.
By addressing both the biological and psychological aspects of the disorder, these treatments provide a comprehensive approach to managing psychosis.
Find a Location
Who is running the clinical trial?
University of MichiganLead Sponsor
1,811 Previous Clinical Trials
6,384,729 Total Patients Enrolled
2 Trials studying Psychosis
237 Patients Enrolled for Psychosis
National Institute of Mental Health (NIMH)NIH
2,801 Previous Clinical Trials
2,661,252 Total Patients Enrolled
46 Trials studying Psychosis
10,671 Patients Enrolled for Psychosis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am between 18 and 65 years old.I have not had thoughts or attempts of suicide in the last 3 months.I have difficulty with thinking or memory.I have been diagnosed with a schizophrenia spectrum disorder.
Research Study Groups:
This trial has the following groups:- Group 1: Cognitive Behavioral Suicide Prevention for psychosis (treatment group)
- Group 2: Services as Usual (SAU; comparison group)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger